Original Research

Published on 20 Sep 2024

Improving the feasibility of deprescribing proton pump inhibitors: GPs’ insights on barriers, facilitators, and strategies

in Drugs Outcomes Research and Policies

Nuša Japelj
Lea Knez
Davorina Petek
Nejc Horvat

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1468750

745 views

Original Research

Published on 19 Sep 2024

The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab

in Drugs Outcomes Research and Policies

F. J. Esplugues
I. Andújar
J. V. Esplugues

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1447324

877 views

Original Research

Published on 16 Sep 2024

The approach of Norm Balance in predicting pharmacists’ intention to collaborate with physicians to improve medication therapy

in Drugs Outcomes Research and Policies

Yifei Liu
Karen B. Farris
Dhananjay Nayakankuppam
Bernard A. Sorofman
Julie M. Urmie
William R. Doucette

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1375529

538 views

Original Research

Published on 13 Sep 2024

The impact of a multidisciplinary team intervention on medication prescription in nursing homes in Catalonia

in Drugs Outcomes Research and Policies

Emilie Anderssen-Nordahl
Eladio Fernández-Liz
Mònica Sabaté Gallego
Montserrat Bosch Ferrer
Margarita Sánchez-Arcilla Rosanas
Mercè Cervera León
Joaquim Miquel Magrinyà
Maria Estrella Barceló-Colomer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1445141

801 views

Original Research

Published on 13 Sep 2024

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

in Drugs Outcomes Research and Policies

Yunhe Fan
Teng Wu
Pengyang Xu
Chuanli Yang
Jie An
Haijia Zhang
Mureed Abbas
Xiushan Dong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1425171

870 views

Clinical Trial

Published on 12 Sep 2024

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

in Drugs Outcomes Research and Policies

Kun Zhang
Shanshan Zhao
Jialin Du
Lan Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1474868

622 views

Original Research

Published on 11 Sep 2024

Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study

in Drugs Outcomes Research and Policies

Xiaosheng Zhu
Huai Huang
Mengjie Zou
Honglin Luo
Tianqi Liu
Shaoliang Zhu
Bin Ye

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1442723

1,139 views

Original Research

Published on 04 Sep 2024

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China

in Drugs Outcomes Research and Policies

Zuojuan Xiang
Ling Ma
Yingzhou Fu
Yong Pan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1411571

751 views

Original Research

Published on 03 Sep 2024

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

in Drugs Outcomes Research and Policies

Yuan Peng
Yuying Zhou
Kaisen Shu
Xu Jia
Yan Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1396378

885 views

Original Research

Published on 03 Sep 2024

Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

in Drugs Outcomes Research and Policies

Qiaoling Yang
Yan Wang
Xuebin Wang
Ping Wang
Boyu Tan
Yijun Li
Huajun Sun
Wenyan Huang
Hongxia Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1463595

905 views

Original Research

Published on 02 Sep 2024

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database

in Drugs Outcomes Research and Policies

Zijian Guo
Jingkai Di
Zhibo Zhang
Shuai Chen
Xingjia Mao
Zehua Wang
Zehui Yan
Xiaoke Li
Zui Tian
Changjiang Mu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1404427

1,361 views

Original Research

Published on 30 Aug 2024

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

in Drugs Outcomes Research and Policies

Yue He
Rong Zhang
Huarui Shen
Yingqi Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1339721

855 views

Original Research

Published on 29 Aug 2024

Medication-related burden and its association with medication adherence among elderly tuberculosis patients in Guizhou, China: a cross-sectional study

in Drugs Outcomes Research and Policies

Yun Wang
Sisi Jian
Zhongfeng Huang
Huijuan Chen
Yuanxia Hu
Shilin Fang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1416005

658 views

Original Research

Published on 29 Aug 2024

Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients

in Drugs Outcomes Research and Policies

Huiying Zong
Yundi Zhang
Fengxi Liu
Xiaoming Zhang
Yilei Yang
Xiaohong Cao
Yue Li
Anan Li
Penglin Zhou
Rui Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1458838

738 views

Specialty Grand Challenge

Published on 26 Aug 2024

Drug outcomes research and policies – trends and challenges

in Drugs Outcomes Research and Policies

Bernd Rosenkranz

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1476849

916 views

Original Research

Published on 23 Aug 2024

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

in Drugs Outcomes Research and Policies

Yichun Shuai
Zhe Chen
Qiaoqian Wan
Jinzheng Wu
Xin Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1419196

1,180 views

Navigation group

Articles

Improving the feasibility of deprescribing proton pump inhibitors: GPs’ insights on barriers, facilitators, and strategies

The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab

The approach of Norm Balance in predicting pharmacists’ intention to collaborate with physicians to improve medication therapy

The impact of a multidisciplinary team intervention on medication prescription in nursing homes in Catalonia

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling

Identification of circulating metabolites linked to the risk of breast cancer: a mendelian randomization study

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China

Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS

Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study

Antihypertensive drug-associated adverse events in osteoarthritis: a study of a large real-world sample based on the FAERS database

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab

Medication-related burden and its association with medication adherence among elderly tuberculosis patients in Guizhou, China: a cross-sectional study

Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients

Drug outcomes research and policies – trends and challenges

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database